Business Wire

Theramex Enters OTC Market with Femarelle®, a Non-hormonal Option to Treat Menopause Symptoms


Theramex, a company dedicated women’s health, recently acquired the Femarelle® product licence to treat menopause symptoms. Femarelle will be available in different markets from the 2nd quarter of 2022. This commercialisation agreement was reached with Se-cure Pharmaceuticals Ltd., the company that developed the product.

Femarelle® offers non-hormonal therapy to balance oestrogen levels in women from peri-menopause through menopause to post-menopause relieving the symptoms and conditions derived from oestrogen loss with the onset of menopause. It addresses specific needs at each menopause stage and is characterised by the natural compound DT56a, an oestrogen receptor modulator, supplemented with stage-appropriate vitamins and minerals. DT56a is developed from the soybean plant taking advantage of the 20 amino acids of soybean in its production process, resulting in a unique compound targeting the oestrogen receptors in the woman's body:

  • Femarelle® Rejuvenate, for women over 40 experiencing menstrual cycle fluctuations, the telltale sign of the onset of perimenopause. Femarelle Rejuvenate restores a woman's hormonal balance, supporting changing moods, loss of skin elasticity and fatigue.
  • Femarelle® Recharge, for women over 50 who may already be feeling classic menopause symptoms such as hot flushes and night sweats and which assists with additional aspects of menopause such as loss of libido.
  • Femarelle ®Unstoppable, for women over 60 who have gone through the bulk of their menopause and are now focused on maintaining bone and vaginal health as they age.

The DT56a compound adheres to oestrogen receptors without being recognised as oestrogen by the body. This unique non-hormonal botanical solution was declared a “first-line treatment for menopause management” at the Presidential Conference of the Annual Congress of the European Society of Gynaecology in 2017. Femarelle® is supported by gynaecologists around the world and has been published in leading journals.

In a survey of 4,000-plus women from different countries, hot flushes and night sweats were the main symptoms in all countries. Femarelle® was found to significantly relieve menopausal symptoms within the first two weeks of treatment and this trend continued following four weeks of treatment in all the countries surveyed. A statistically significant reduction was found at each week of treatment1.

With this move, Theramex steps up its commitment to provide women with an effective and safe alternative to menopause hormone therapy. “Our main objective is to meet women’s health needs around the world,” said Theramex chief executive Robert Stewart . “Not only their current needs but future ones too in order to improve their lives. With Femarelle®, we are adding to our portfolio an alternative for women with untreated menopause who are reluctant to use hormone therapy”.

Esti Grunbaum, Vice President BD & Marketing at Se-cure Pharmaceuticals Ltd., said: “We are very excited about this collaboration with Theramex. Together we will provide women with more menopausal symptom treatment options”.

Jose Naranjo, Theramex Vice President Marketing, said: “We offer a non-hormonal option to healthcare professionals, backed by scientific studies verifying its safety and efficacy. This allows us to cover an unmet need for these women who will now be heard, understood and have access to a treatment that will provide them with greater adherence and therefore a better quality of life”.

About Theramex

Theramex is a leading global speciality pharmaceutical company dedicated to women and their health. We support women at every stage of their lives by providing a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis. Our commitment is to listen to and understand our patients, serve their needs and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them by providing patient-focused and effective solutions that care for and support women through every stage of life.

About Se-cure Pharmaceuticals Ltd.

Se-cure Pharmaceuticals Ltd. is a research-driven biotech company focused on the discovery and development of therapeutic solutions originating from botanical sources with an emphasis on safety of use. Founded in 1997, Se-cure’s competencies include target-manipulated germination and proprietary agro-technologies used to engineer botanicals into tissue-targeted therapeutics.

Se-cure develops unique botanical therapies that integrate the pharmaceutical world with the supplement world, balancing them both to create highly effective therapies that can be taken for the long-term, improving quality of life without incurring risks. The API in our products are developed in-house, providing proprietary products with vast scientific support.

Se-cure has a state-of-the-art biotech-pharmaceutical manufacturing facility operating under rigorous quality control standards, producing standardised nutraceuticals with swift efficacy and the highest safety. We are dedicated to bringing forth unique botanical therapies that provide proven relief of symptoms while avoiding the risks of the conventional options

1 Genazzani A., Nachtigall L., Panay N. & Yoles I. Symposium: 2 Continents, 3 cultures, 4 countries, 2,000 women and Femarelle®; 13th World Congress on Menopause. Rome, Italy June 2011.
Sánchez-Borrego R., Mendoza N., Llaneza P. A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms; Climacteric. 2015;18(6):813-6.
Chen F.P et al. Efficacy of Femarelle for the treatment of climacteric syndrome in postmenopausal women: An open label trial. Taiwan J Obstet Gynecol. 2016;55(3):336-40.


To view this piece of content from, please give your consent at the top of this page.

Contact information

Jesús López | Associate Director, Communication & Digital |

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Percona Platform Unifies Open Source Databases, Supports Private Database-as-a-Service Deployments7.12.2021 17:20:00 EET | Press release

Percona, a leader in open source database software and services, today announced Percona Platform to bring together database distributions, support expertise, services, management and automated insights into a single product. Building on the company’s expertise with databases including MySQL, PostgreSQL and MongoDB, the new Percona Platform will simplify how users monitor, manage and optimize their database instances across any infrastructure. In addition, Percona Platform will enable developers and database administrators to run their own private Database-as-a-Service (DBaaS) instances. This launch will preview the Percona Platform, allowing users to unify the entire database experience from packages and backup to monitoring and management, with general availability in early 2022. Percona brings together distributions of MySQL, PostgreSQL and MongoDB including a range of open source tools for data backup, availability and management. It also includes Percona Monitoring and Management

Zencity Accelerates Collaboration Between Communities and Local Governments by Acquiring Civil Space7.12.2021 17:16:00 EET | Press release

Zencity, the leading global community engagement technology platform for local governments, announced the acquisition of cutting edge digital engagement startup Civil Space, based in Vancouver, Canada. The deal immediately adds to Zencity’s powerful suite the capability to create and capture deep, meaningful, equitable, two-way conversations between governments and their residents. With its acquisition of Civil Space, Zencity emerges as the most effective, inclusive and wide-reaching community engagement platform available for local governments, built around two core principles: Lowering the barriers to participation by meeting residents where they are and hearing many more voices; and Making it easier for governments to turn the resulting, broadened community input into action. The combination of Zencity’s analysis of broad community input with Civil Space’s direct engagement platform will enable local leaders to further enhance the feedback they are leveraging. The information will b

MCR Acquires Cloud-Based Hotel Management Platform Optii7.12.2021 17:00:00 EET | Press release

MCR, the 4th-largest hotel owner-operator in the United States and one of Fast Company’s 10 Most Innovative Travel Companies of 2020, has acquired Optii, the only predictive, cloud-based technology for improved hotel operations. Optii will continue to be a standalone company with its existing management team of CEO Katherine Grass, Founder and CSO Soenke Weiss and CRO Deborah Pevenstein. MCR’s portfolio of 140 branded and independent hotels will be arms-length customers of Optii, which will continue to offer its product to forward-thinking hotel companies. No data will be shared with MCR. MCR will mobilize its 4,000 hotel team members — who will utilize Optii for 20,000 guestrooms per day — to push for innovative product enhancements. Stayntouch property management system software, another standalone company owned by MCR, will integrate with Optii. A data-driven platform powered by artificial intelligence, Optii has revolutionized housekeeping technology, optimizing labor and cleaning

Alation Forges Strategic Partnerships With Bigeye and Soda7.12.2021 17:00:00 EET | Press release

Alation, Inc., the leader in enterprise data intelligence solutions, today announced formal partnership agreements with Bigeye and Soda, leading data observability vendors. The partnerships provide customers with the choice to select the best data observability partner for their organisation’s needs. Alation’s active data governance helps organisations drive data culture by providing all data users, regardless of technical skillset, with access to quality data. Bigeye’s data observability platform helps detect data quality issues and ensures reliable data pipelines. Soda’s data observability platform allows teams to discover, prioritise, and collaboratively resolve data issues. The platforms are invaluable for alerting technical users to deeper data quality issues, such as the trustworthiness of the data or its usability. Alation’s integrations with Bigeye and Soda provide all data consumers, from business users to data scientists, with a single-pane-of-glass view into the trustworthin

Acadia and Capitolis Launch SA-CCR Optimization Service7.12.2021 16:30:00 EET | Press release

Acadia, the leading industry provider of integrated risk management services for the derivatives community, and Capitolis, the leading SaaS platform that drives financial resource optimization for capital markets, today announced the launch of SA-CCR Optimization. SA-CCR Optimization will bring considerable cost savings to firms subject to the Standard Approach to Counterparty Credit Risk (SA-CCR) regulations, focusing on specific FX products such as FX forwards, options, deliverable swaps and cross-currency swaps. This press release features multimedia. View the full release here: With SA-CCR Optimization, banks and participating financial institutions provide trade data, which Acadia and Capitolis process and use to generate a series of FX transactions that reduce capital requirements, leaving each client’s net FX risk profile largely unchanged. “The newest wave of capital regulation is pushing firms to be more mindful of capi

 Earnix Welcomes Industry Veteran Craig Conway to its Board of Directors7.12.2021 16:30:00 EET | Press release

Earnix, a global provider of advanced AI-driven rating, pricing, and product personalization solutions for insurance and banking, today announced the appointment of Craig Conway to the board of directors. Conway led multiple technology companies to success including PeopleSoft, One Touch Systems, and TGV Software as President and CEO. Under his leadership PeopleSoft became the world’s second-largest provider of enterprise business software. Additionally, he held instrumental senior operating positions including as Executive Vice President at Oracle Corporation. Currently, Conway serves on the boards of, Nutanix, Sitecore, and IFS. Also, he served as Executive Chairman for Guidewire, leading the company to IPO in 2012. Conway’s deep market expertise and seasoned experience as an influential chairman, board member and senior executive stand to bolster Earnix’s leadership of mission-critical systems for global insurers and banks. “We are thrilled to have Craig, a proven lea

DNP Develops Interposer, a Primary Component in Next-Generation Semiconductor Packaging7.12.2021 16:05:00 EET | Press release

Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) has developed an interposer, a high-performance intermediate device that electrically connects multiple chips and substrates. The interposer is expected to play a key role in next-generation semiconductor packaging. This press release features multimedia. View the full release here: Layer Structure (Graphic: Business Wire) DNP also has participated in Jisso Open Innovation of Tops 2 (JOINT2), targeting further functional developments for mass-production in 2024. JOINT2 is a consortium comprising 12 companies developing semiconductor packaging materials, substrates, and equipment. Showa Denko Materials Co., Ltd. is the managing company, and was selected for the Research and Development Project of the Enhanced Infrastructures for Post-5G Information and Communication Systems by the New Energy and Industrial Technology Development Organization (NEDO). “Through cooperation with the oth

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom